...
首页> 外文期刊>Transplantation: Official Journal of the Transplantation Society >Delayed omega-3 fatty acid supplements in renal transplantation. A double-blind, placebo-controlled study.
【24h】

Delayed omega-3 fatty acid supplements in renal transplantation. A double-blind, placebo-controlled study.

机译:在肾脏移植中延迟补充omega-3脂肪酸。一项双盲,安慰剂对照的研究。

获取原文
获取原文并翻译 | 示例

摘要

An earlier reported trial suggests that omega-3 fatty acids in fish oil supplements at 6 g/day with administration commencing at the time of engraftment may reduce acute CsA renal dysfunction. When started at the time of renal transplant, there are improvements in renal hemodynamics and blood pressure, and a decrease in rejection episodes. To examine the effect of later introduction of omega-3 fatty acids, 133 cadaver renal transplant recipients received CsA, prednisone, and AZA for 16 weeks (period 1). If patients were stable without rejection or infection activity, they were randomized to 9 g of eicosapentanoic acid (EPA), 18 g of EPA, 9 g of corn oil, or 18 g of corn oil in 1-g capsules as supplements. Glomerular filtration rate, renal blood flow, number of rejection episodes, blood pressure, and episodes of CsA nephrotoxicity were followed for 26 weeks in a double-blind manner (period 2). Ninety patients were evaluable and completed the protocol. There were 50 corn oil placebo patients, 22 low doseEPA patients, and 18 high dose EPA patients. In period 1, there were 27 rejection episodes in 21 patients without differences among subsequent treatment groups. In period 2, there were 13 rejection episodes in 4 patients. No patient with an EPA level in plasma statistically higher than placebo had a rejection episode. All allografts functioned for the entire 6 months with none lost to rejection. All 5 episodes of acute CsA nephrotoxicity occurred in placebo-treated patients without differences in whole blood CsA among toxic patients, other placebo patients, and EPA-treated recipients. At the end of the study, there were no differences in glomerular filtration rate, renal blood flow, or creatinine clearance among groups. Diastolic blood pressure fell by 9 mmHg during period 2 in high dose fish oil recipients and by 10 mmHg in low dose fish oil recipients (P < 0.05), while it rose by 2 mmHg in placebo patients. No serious adverse effects of EPA supplements were noted, although compliance based on plasma EPA waserratic. Based on our experience and that in the literature, administration of omega-3 fatty acids for purposes of kidney protection would seem to be most useful when started early after surgery. Late administration in our study was associated with minor clinical benefits.
机译:一项较早报道的试验表明,鱼油补充剂中的omega-3脂肪酸以6 g / day的剂量在植入时开始给药,可减轻急性CsA肾功能不全。在肾移植时开始使用时,肾血液动力学和血压会有所改善,排斥反应的发生率会降低。为了检查后来引入omega-3脂肪酸的效果,有133名尸体肾移植受者接受了CsA,泼尼松和AZA治疗16周(第1期)。如果患者稳定,没有排斥反应或感染活动,则将他们随机分为1克胶囊中的9克二十碳五烯酸(EPA),18克EPA,9克玉米油或18克玉米油作为补充剂。以双盲方式(第2期)随访肾小球滤过率,肾血流量,排斥反应次数,血压和CsA肾毒性发作26周。 90名患者是可评估的,并完成了方案。有50名玉米油安慰剂患者,22名低剂量EPA患者和18名高剂量EPA患者。在第1阶段中,有21例患者发生了27例排斥反应,后续各治疗组之间没有差异。在第2期中,有4例患者发生了13次排斥反应。血浆EPA水平在统计学上没有高于安慰剂的患者没有排斥反应。所有同种异体移植物在整个6个月内都正常运转,没有一个因排斥而丢失。急性CsA肾毒性的所有5次发作均发生在安慰剂治疗的患者中,而中毒患者,其他安慰剂患者和EPA治疗的接受者的全血CsA没有差异。在研究结束时,各组之间的肾小球滤过率,肾血流量或肌酐清除率无差异。高剂量鱼油接受者的舒张压在第2阶段下降了9 mmHg,低剂量鱼油接受者的舒张压下降了10 mmHg(P <0.05),而安慰剂患者则上升了2 mmHg。尽管基于血浆EPA的依从性依旧不佳,但未发现EPA补充剂的严重不利影响。根据我们的经验和文献,在术后早期开始使用omega-3脂肪酸进行肾脏保护似乎最为有用。我们研究中的晚期给药与较小的临床获益相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号